Latest Hotspot

Agomab Begins Phase I Trial of AGMB-447 in Healthy Subjects and IPF Patients

25 December 2023
3 min read

Agomab Therapeutics NV has revealed the initiation of a pioneering Phase 1 clinical trial by administering the initial dose of AGMB-447 to a participant. This novel small molecule, with a restrictive function to the lungs when inhaled, acts as an inhibitor to ALK5. The ongoing trial is assessing the effects of AGMB-447 both in individuals without underlying health conditions and in individuals diagnosed with idiopathic pulmonary fibrosis.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The initial clinical study for AGMB-447 encompasses an evaluation of both a single dose escalation and multiple dose escalations in healthy volunteers, with subsequent administrations of AGMB-447 to individuals with IPF over a duration of 14 days. This clinical study is being carried out with a combined total of 76 participants and IPF sufferers in the United Kingdom. The main objectives of the study are to assess the drug's safety and patient comfort. Additional study aims involve the examination of AGMB-447's absorption and distribution within the body, as well as at the site of action.

"With the initiation of clinical testing for AGMB-447, Agomab's second compound targeting ALK5, we are embarking on a thrilling journey and reaching a significant stage," commented Andrea Sáez, Chief Development Officer at Agomab Therapeutics. "This drug candidate holds the promise of being a vital advancement in the treatment arsenal for individuals enduring IPF and additional lung-related fibrotic conditions."

Andrea Sáez also noted, "Owing to its lung-centric distribution, AGMB-447 is designed to specifically and yet gently intervene with TGFβ, a crucial contributor to fibrosis, within the lungs where it's needed most."

At present, AGMB-447 remains an experimental therapy and has yet to garner approval from health regulatory agencies. Its effectiveness and safety record are still under review.

Defined as a compound specifically targeting the lungs for the purpose of inhibiting ALK5, AGMB-447 is intended for the management of Idiopathic Pulmonary Fibrosis along with other fibrotic diseases affecting the respiratory system. AGMB-447 has been meticulously crafted to deliver a powerful yet careful inhibition of ALK5 within the pulmonary system, while its swift breakdown by hydrolysis in the bloodstream minimizes the likelihood of significant exposure throughout the body.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面, 文本, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of December 23, 2023, there are 29 investigational drugs for the ALK5 target, including 39 indications, 32 R&D institutions involved, with related clinical trials reaching 78, and as many as 4059 patents.

AGMB-447 is a small molecule drug being developed for the treatment of idiopathic pulmonary fibrosis. By targeting ALK5, the drug aims to modulate the TGF-β pathway and potentially inhibit the formation of scar tissue in the lungs. Currently in Phase 1 of clinical development, AGMB-447 holds promise as a potential therapeutic option for patients suffering from this debilitating respiratory disease.

图形用户界面, 文本, 应用程序

描述已自动生成

Understanding STAT3 Inhibitors and Methods to Keep Abreast of Their Recent Developments
Understanding STAT3 Inhibitors and Methods to Keep Abreast of Their Recent Developments
25 December 2023
The development of STAT3 inhibitors will be increasingly valued in the future, and targeting the STAT3 signaling pathway has become a promising strategy for the treatment of various cancers.
Read →
What are the advantages of Oligonucleotide drugs?
"What" Series
2 min read
What are the advantages of Oligonucleotide drugs?
25 December 2023
The emergence of oligonucleotide drugs makes it possible to actively design drug sequences to target and silence disease genes.
Read →
Decoding Cadonilimab: a comprehensive study of its R&D trends and its clinical results in 2023 ESMO_ASIA
ESMO 2023
4 min read
Decoding Cadonilimab: a comprehensive study of its R&D trends and its clinical results in 2023 ESMO_ASIA
22 December 2023
At the 2023 ESMO_ASIA , the latest clinical results of Cadonilimab were presented, demonstrating its potential therapeutic effect on HCC and laying a solid foundation for the next wave of research.
Read →
FDA fast-tracked Amgen's Tarlatamab for advanced small cell lung cancer treatment
Latest Hotspot
3 min read
FDA fast-tracked Amgen's Tarlatamab for advanced small cell lung cancer treatment
22 December 2023
FDA has accorded an expedited evaluation to the drug Tarlatamab, developed by Amgen, which is aimed at treating advanced-stage small cell lung cancer.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.